Latest News
Featured
Huge congratulations to Oguzhan, David, and the exceptional BillionToOne team on securing $130 million in an oversubscribed Series D funding round. This funding will further revolutionize the prenatal screening and oncology diagnostics landscape.
Mammoth and Regeneron will collaborate on in vivo CRISPR-based gene editing therapies in a deal worth $100 million upfront plus $370 million in milestones per target.
Fauna Bio improving human health by leveraging animal genomics, today announced a multi-year agreement with Eli Lilly and Company to apply Fauna's Convergence™ artificial intelligence (AI) platform to support preclinical drug discovery efforts in obesity.
Interface Bio emerges with $3m to harness the microbiome against inflammation. The AI-powered platform identifies bacterial natural products with the potential to modulate the immune system and reduce inflammation.
BillionToOne appoints Dr. Gary Palmer as Chief Medical Officer, Oncology; Launches Northstar Select™ and Northstar Response™ Liquid Biopsy Assays for Commercial Use
BillionToOne Secures $83.5M in Private Funding, Loan Facility; Shows Clinical Performance of NIPT
Bayer and Mammoth Biosciences today announced a strategic collaboration and option agreement for the use of Meliora Therapeutics Raises $11M Seed Financing to Develop First Mechanism Of Action Atlas in Oncology
Bayer and Mammoth Biosciences today announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies
Vertex Pharmaceuticals and Mammoth Biosciences today announced a new partnership to develop in vivo gene-editing therapies for two genetic diseases using Mammoth’s next-generation CRISPR systems.
Fauna Bio raises $9 Million to expand the comparative genomics platform for novel target discovery. This round is led by LifeForce Capital with participation from previous investors including Pacific 8 Ventures, True Ventures, and more.
Copyright © 2023 Pacific 8 Ventures